← All trials
NCT05232630
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 20, 2022
- Primary completion
- Jun 20, 2024
- Completion date
- Jun 20, 2024
- First posted
- Feb 10, 2022
- Last posted
- Oct 21, 2022
- Enrollment
- 20
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hospital Ruber InternacionalLead sponsor
- Zogenix, Inc.Collaborator
- Hospital Ruber InternacionalOverall official - principal investigator
- Hospital Ruber InternacionalReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.